Arango-Rodriguez ML, Ezquer F, Ezquer M, Conget P. Could cancer and infection be adverse effects of mesenchymal stromal cell therapy? World J Stem Cells 2015; 7(2): 408-417 [PMID: 25815124 DOI: 10.4252/wjsc.v7.i2.408]
Corresponding Author of This Article
Paulette Conget, PhD, Center for Regenerative Medicine, School of Medicine Clínica Alemana Universidad del Desarrollo, Av. Las Condes 12438, Lo Barnechea, Santiago 7710162, Chile. pconget@udd.cl
Research Domain of This Article
Cell Biology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Mar 26, 2015; 7(2): 408-417 Published online Mar 26, 2015. doi: 10.4252/wjsc.v7.i2.408
Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?
Martha L Arango-Rodriguez, Fernando Ezquer, Marcelo Ezquer, Paulette Conget
Martha L Arango-Rodriguez, Fernando Ezquer, Marcelo Ezquer, Paulette Conget, Center for Regenerative Medicine, School of Medicine Clínica Alemana Universidad del Desarrollo, Santiago 7710162, Chile
Author contributions: Arango-Rodriguez ML, Ezquer F, Ezquer M and Conget P contributed to this paper.
Supported by FONDECYT to Paulette Conget, No. 1130760.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Paulette Conget, PhD, Center for Regenerative Medicine, School of Medicine Clínica Alemana Universidad del Desarrollo, Av. Las Condes 12438, Lo Barnechea, Santiago 7710162, Chile. pconget@udd.cl
Telephone: +56-2-23279302 Fax: +56-2-23279306
Received: July 12, 2014 Peer-review started: July 12, 2014 First decision: September 24, 2014 Revised: October 1, 2014 Accepted: November 7, 2014 Article in press: November 10, 2014 Published online: March 26, 2015 Processing time: 251 Days and 10.1 Hours
Core Tip
Core tip: Mesenchymal stem cells (MSCs) derived from different origins have recently received much attention as potential therapeutic. However, such cells also appear to have essential functions in building and supporting tumor microenvironments. Here, we review the effect of MSCs on tumor establishment, as also susceptibility to infection and its progression. The literature reveals incongruity regarding the impact of MSCs on the development of cancer and infection; such paradoxical effect might be attributed to differences in isolation and expansion conditions, the source and dose of the cells, the administration route and its timing and host characteristics. MSCs immunomodulatory potential seems to be the leading mechanism responsible for such effects.
